The University of Michigan-linked vaccination technology developer has pivoted from its previous focus on antimicrobial ointments for skin infections.
BlueWillow Biologics, a US-based vaccine developer based on University of Michigan research, has closed a $10m round backed by the university’s Michigan Invests in New Technology Startups (Mints) fund, Crain’s Detroit Business has reported.
The round was led by VC firm North Coast Technology Investors with participation from Line Moon Ventures.
Founded in 2000 as NanoBio, BlueWillow Biologics previously commercialised antimicrobial ointments to treat skin infections but has now switched to develop medical vaccines that can be administered as a…